Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WOKVAC With Neoadjuvant Chemotherapy and HER2-Targeted Therapy in Breast Cancer
NCT04329065Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- Apr 2022
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of WOKVAC in breast cancer, sponsored by University of Washington. Started Apr 2022; status: recruiting.
02
Drugs
WOKVAC
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04329065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04329065.